Takeda Pharmaceutical Company Limited
- Jurisdiction
Japan - LEI
549300ZLMVP4X0OGR454 - ISIN
US8740602052 (TAK )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€21.96 83.0% undervalued - Financial strength (Piotroski F-Value)
-
7
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. Read full profile
Fundamentals
- Net revenue
€25.88B - Gross margin
57.4% - EBIT
€2.34B - EBIT margin
9.0% - Net income
€790.96M - Net margin
3.1%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
- Last dividend amount
-
$0.28 - Ex date
-
- Payment date
-
- Dividend payout ratio
-
226.2%
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: October 27, 2023 (Q2 2023)